Showing results (21-30 of 77) with videos related to

Sort By:
Pageof 8
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|September 2, 2015
CD34-Selected Allogeneic Hematopoietic Stem Cell Transplantation for Patients with Relapsed, High-Risk Multiple MyelomaEric Smith, Sean M Devlin, Satyajit Kosuri, et al.
American Journal of Hematology|September 24, 2021
A phase I/II study of ixazomib, pomalidomide, and dexamethasone for lenalidomide and proteasome inhibitor refractory multiple myeloma (Alliance A061202)Peter M Voorhees, Vera J Suman, Sascha A Tuchman, et al.
British Journal of Haematology|September 28, 2007
Risk-adapted autologous stem cell transplantation with adjuvant dexamethasone +/- thalidomide for systemic light-chain amyloidosis: results of a phase II trialAdam D Cohen, Ping Zhou, Joanne Chou, et al.
Blood Advances|February 24, 2023
Lenalidomide-associated B-cell ALL: clinical and pathologic correlates and sensitivity to lenalidomide withdrawalMark B Geyer, Brian C Shaffer, Bhavana Bhatnagar, et al.
Clinica Chimica Acta; International Journal of Clinical Chemistry|February 5, 2021
Using MALDI-TOF mass spectrometry in peripheral blood for the follow up of newly diagnosed multiple myeloma patients treated with daratumumab-based combination therapyMarion Eveillard, Neha Korde, Amanda Ciardiello, et al.
Leukemia & Lymphoma|January 13, 2017
Gain of chromosome 1q portends worse prognosis in multiple myeloma despite novel agent-based induction regimens and autologous transplantationGunjan L Shah, Heather Landau, Dory Londono, et al.
Cancer Immunity|July 24, 2003
Expression of cancer/testis (CT) antigens MAGE-A1, MAGE-A3, MAGE-A4, CT-7, and NY-ESO-1 in malignant gammopathies is heterogeneous and correlates with site, stage and risk status of diseaseMadhav V Dhodapkar, Keren Osman, Julie Teruya-Feldstein, et al.
Clinical Biochemistry|September 25, 2016
Treatment of multiple myeloma with monoclonal antibodies and the dilemma of false positive M-spikes in peripheral bloodKazunori Murata, Samuel I McCash, Brittany Carroll, et al.
Leukemia & Lymphoma|June 1, 2022
Continuous induction with lenalidomide/dexamethasone versus autologous stem cell transplantation in newly diagnosed multiple myeloma: a case for response-adapted approachOscar B Lahoud, Heather Landau, James Nguyen, et al.
British Journal of Haematology|January 10, 2006
Doxorubicin and dexamethasone followed by thalidomide and dexamethasone is an effective well tolerated initial therapy for multiple myelomaHani Hassoun, Lilian Reich, Virginia M Klimek, et al.
Pageof 8